Literature DB >> 30362086

siRNA Blocking of Mammalian Target of Rapamycin (mTOR) Attenuates Pathology in Annonacin-Induced Tauopathy in Mice.

Mohamed Salama1,2, Sara El-Desouky3, Aziza Alsayed3, Mahmoud El-Hussiny3, Khaled Magdy3, Emad Fekry4, Osama Shabka4, Sabry A El-Khodery5, Mohamed A Youssef5, Mohamed Sobh6, Wael Mohamed7,8.   

Abstract

Tauopathy is a pathological hallmark of many neurodegenerative diseases. It is characterized by abnormal aggregates of pathological phosphotau and somatodendritic redistribution. One suggested strategy for treating tauopathy is to stimulate autophagy, hence, getting rid of these pathological protein aggregates. One key controller of autophagy is mTOR. Since stimulation of mTOR leads to inhibition of autophagy, inhibitors of mTOR will cause stimulation of autophagy process. In this report, tauopathy was induced in mice using annonacin. Blocking of mTOR was achieved through stereotaxic injection of siRNA against mTOR. The behavioral and immunohistochemical evaluation revealed the development of tauopathy model as proven by deterioration of behavioral performance in open field test and significant tau aggregates in annonacin-treated mice. Blocking of mTOR revealed significant clearance of tau aggregates in the injected side; however, tau expression was not affected by mTOR blockage.

Entities:  

Keywords:  Autophagy; Neurodegeneration; Tauopathy; mTOR; siRNA

Mesh:

Substances:

Year:  2018        PMID: 30362086     DOI: 10.1007/s12640-018-9974-3

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  22 in total

Review 1.  Autophagy as a regulated pathway of cellular degradation.

Authors:  D J Klionsky; S D Emr
Journal:  Science       Date:  2000-12-01       Impact factor: 47.728

Review 2.  mTOR signaling in growth control and disease.

Authors:  Mathieu Laplante; David M Sabatini
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

Review 3.  Autophagy and aging: the importance of maintaining "clean" cells.

Authors:  Ana Maria Cuervo; Ettore Bergamini; Ulf T Brunk; Wulf Dröge; Martine Ffrench; Alexei Terman
Journal:  Autophagy       Date:  2005-10-13       Impact factor: 16.016

Review 4.  The role of TOR in autophagy regulation from yeast to plants and mammals.

Authors:  Sandra Díaz-Troya; María Esther Pérez-Pérez; Francisco J Florencio; José L Crespo
Journal:  Autophagy       Date:  2008-10-08       Impact factor: 16.016

5.  Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain.

Authors:  Xu Li; Irina Alafuzoff; Hilkka Soininen; Bengt Winblad; Jin-Jing Pei
Journal:  FEBS J       Date:  2005-08       Impact factor: 5.542

6.  Rapamycin treatment augments motor neuron degeneration in SOD1(G93A) mouse model of amyotrophic lateral sclerosis.

Authors:  Xiaojie Zhang; Liang Li; Sheng Chen; Dehua Yang; Yi Wang; Xin Zhang; Zheng Wang; Weidong Le
Journal:  Autophagy       Date:  2011-04-01       Impact factor: 16.016

7.  Tau suppression in a neurodegenerative mouse model improves memory function.

Authors:  K Santacruz; J Lewis; T Spires; J Paulson; L Kotilinek; M Ingelsson; A Guimaraes; M DeTure; M Ramsden; E McGowan; C Forster; M Yue; J Orne; C Janus; A Mariash; M Kuskowski; B Hyman; M Hutton; K H Ashe
Journal:  Science       Date:  2005-07-15       Impact factor: 47.728

8.  Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: implication for Alzheimer disease.

Authors:  Zhi Tang; Erika Bereczki; Haiyan Zhang; Shan Wang; Chunxia Li; Xinying Ji; Rui M Branca; Janne Lehtiö; Zhizhong Guan; Peter Filipcik; Shaohua Xu; Bengt Winblad; Jin-Jing Pei
Journal:  J Biol Chem       Date:  2013-04-12       Impact factor: 5.157

Review 9.  Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options.

Authors:  A C Ludolph; J Kassubek; B G Landwehrmeyer; E Mandelkow; E-M Mandelkow; D J Burn; D Caparros-Lefebvre; K A Frey; J G de Yebenes; T Gasser; P Heutink; G Höglinger; Z Jamrozik; K A Jellinger; A Kazantsev; H Kretzschmar; A E Lang; I Litvan; J J Lucas; P L McGeer; S Melquist; W Oertel; M Otto; D Paviour; T Reum; A Saint-Raymond; J C Steele; M Tolnay; H Tumani; J C van Swieten; M T Vanier; J-P Vonsattel; S Wagner; Z K Wszolek
Journal:  Eur J Neurol       Date:  2009-03       Impact factor: 6.089

10.  Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice.

Authors:  Sefika Ozcelik; Graham Fraser; Perrine Castets; Véronique Schaeffer; Zhiva Skachokova; Karin Breu; Florence Clavaguera; Michael Sinnreich; Ludwig Kappos; Michel Goedert; Markus Tolnay; David Theo Winkler
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

View more
  2 in total

1.  Parkinson's Disease and Impairment in Mitochondrial Metabolism: A Pathognomic Signature.

Authors:  Biswadeep Das; Sriya Priyadarshini Dash; Swabhiman Mohanty; Paritosh Patel
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Tauopathies: new perspectives and challenges.

Authors:  Yi Zhang; Kai-Min Wu; Liu Yang; Qiang Dong; Jin-Tai Yu
Journal:  Mol Neurodegener       Date:  2022-04-07       Impact factor: 14.195

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.